Abstract library

680 results for "cluster analysis".
#2086 miRNA Expression Defines Novel Subgroups of Small Intestinal Neuroendocrine Tumors
Introduction: Epigenetic dysregulation frequently occurs in cancers. Here we present the largest survival related miRNA profiling study to date of small intestinal neuroendocrine tumors (SI-NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: PhD Yvonne Arvidsson
#167 Localization of Sporadic Neuroendocrine Tumors by Gene expression Analysis of Their Metastases
Introduction: Primary neuroendocrine tumors (NETs) are rare and often difficult to detect, leading to diagnosis late in their development. Cases in which the primary cannot be located are denoted as CUP-Syndrome.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dipl. Biol. Nicole Posorski
#1222 The Clinical Utility of Blood Derived Gene Cluster Analysis of Neuroendocrine Tumors Using Neoplasia Hallmark Criteria
Introduction: We developed a multianalyte blood (51 transcript) assay (MAAA) for GEP-NETs with a sensitivity (98%) and specificity (97%).
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Drozdov I, Modlin I, ...
Keywords: PCR
#1916 Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT
Introduction: Prediction of PRRT efficacy is critical. We tested a blood-based multigene NET transcript analysis (NETest) to predict efficacy in 2 PRRT-treated NET cohorts. The algorithm comprises >50 genes + clusters of growth factor signaling (GFS) and metabolism (MTB).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Lisa Bodei
Authors: Bodei L, Kidd M, Singh A, Severi S, ...
Keywords: PRRT, efficacy
#1684 An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)
Introduction: In ELECT, LAN 120mg every 4 weeks significantly reduced octreotide rescue therapy use for symptomatic CS control vs placebo (PBO).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: George Camba
Keywords: SSA, carcinoid, symptoms
#2253 The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-Trend and Outcome Analysis from 587 Consecutive Resections at a High-Volume Institution
Introduction: Reflecting their rarity and heterogeneity, Pan-NENs represent a clinical dilemma and there is a scarcity of data regarding their long-term follow-up after resection.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Tommaso Pollini
#1184 A National Pathology Registration Analysis of Applied Terminology in Pulmonary Neuroendocrine Tumors/Carcinomas: Is the WHO 2004 Classification in Line with Clinical Practice?
Introduction: Nomenclature of the WHO 2004 should be used for pulmonary neuro-endocrine tumors (NET) and carcinomas (NEC) classification.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Jules Derks
Keywords: NET, Diagnosis
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H, ...
#696 Downgrading Due to Ki-67 Index Assessment with Image Analysis
Introduction: The latest WHO classification for neuroendocrine tumors (NET) defines their grade according to Ki-67 and mitotic index. These parameters have both shown to be prognostic.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Marie-Louise Van Velthuysen
#733 Analysis of Predictive Markers of Response to Chemotherapy in Microdissected Components of Mixed Neuroendocrine/non-Neuroendocrine Carcinomas
Introduction: Mixed neuroendocrine (NE)/non-NE carcinomas lack pathological or molecular prognostic or predictive markers.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Marco Volante